A story in the April 18, 2005, issue of BioWorld Today should have said Roche's 2003 option agreement with Memory Pharmaceuticals for the nicotinic alpha-7 target provides funding from Roche after the Phase IIa stage.

Editor's Note: The correction has been made in BioWorld Online.